Clinical trial
A Safety and Efficacy Study of Oral Cladribine in Subjects With…
NCT00213135 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00213135 |
|---|---|
| Title | A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) |
| Official title | A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) |
| Acronym | CLARITY |
| Lead sponsor | EMD Serono, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Drug, Other |
| Interventions | Cladribine 5.25 mg/kg, Cladribine 3.5 mg/kg, Placebo |
| Enrollment | 1,326 |
| Start date | Apr 1, 2005 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Sep 21, 2005 |
| Last update posted | Feb 7, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: